Pomerantz LLP has initiated an investigation into Biohaven Ltd. (NYSE: BHVN) on behalf of its investors, examining potential claims of securities fraud or other unlawful business practices by the company and certain officers or directors. Investors impacted by these concerns are advised to contact Danielle Peyton for further information.

The investigation follows a significant announcement made by Biohaven on May 14, 2025. The company disclosed that the Division of Neurology 1 within the FDA’s Office of Neuroscience decided to extend the PDUFA (Prescription Drug User Fee Act) date for the troriluzole new drug application (NDA) by three months. This extension is intended to allow for a comprehensive review of recent submissions from Biohaven related to information requests from the FDA. Furthermore, the FDA division indicated its intention to hold an advisory committee meeting to discuss the application, though a specific date has not yet been set.

Following this news, Biohaven’s stock price experienced a substantial decline. On May 15, 2025, the stock fell by $3.84 per share, representing a 19.53% drop, closing at $15.82 per share. This sharp decrease in stock value is a central point of concern for the ongoing investigation.

Pomerantz LLP, a prominent law firm with a global presence, is widely recognized for its expertise in corporate, securities, and antitrust class litigation. The firm, founded by Abraham L. Pomerantz, has a long-standing history of pioneering securities class actions and continues its legacy of advocating for victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The firm has a strong track record of securing multi-million-dollar damages awards for its class members.